Perilla is an East Asian herb used in two oral preparations, plant omega-3 seed oil and antioxidant leaf extract, for seasonal allergies, digestive comfort, and longevity. Moderate human evidence supports relieving nasal and eye allergies, bloating, constipation, and mild knee pain, and preserving heel bone density, whereas cholesterol, cognitive, blood pressure, mood, and blood-clotting findings are conflicted. Studied doses show placebo-like adverse-event rates, though severe seed allergies occur. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Serum LDL-C and ApoB | No established target; reduction from individual baseline | Efficacy marker: perilla seed oil (3 g/day) significantly lowers LDL-C and ApoB (fasted at baseline, 12 weeks, and 6 months) |
| Erythrocyte ALA and EPA (%) | No established target; increase from individual baseline | Efficacy marker: confirms absorption and elongation of seed oil ALA via red blood cell gas chromatography (baseline and 8–12 weeks) |
| Serum TRACP-5b | 170–590 mU/dL in men; 120–420 mU/dL in premenopausal women; 250–760 mU/dL in postmenopausal women (standard reference range) | Efficacy marker: 12-month seed oil intake lowers bone resorption (morning fasted serum, paired with annual calcaneal ultrasound bone densitometry %YAM) |
| Collagen-ADP Closure Time (PFA-100) | 62–100 seconds (standard reference range) | Safety and efficacy check: 4.8 g/day seed oil prolongs closure time (baseline and 8 weeks if co-administered with antiplatelet or anticoagulant agents) |
| Perilla Seed Allergy Testing | No established target; qualitative absence of sensitization | Safety check: rules out IgE sensitization before use in seed-allergic individuals via specialist allergy workups (no commercial standardized assay exists) |
Cadence: Baseline fasted blood panels and specialist allergy evaluation (in seed-allergic individuals) before initiation; re-evaluation at 4 weeks (tolerability and gastrointestinal comfort), 8–12 weeks (erythrocyte fatty-acid incorporation, lipids, and platelet closure time), and every 6–12 months thereafter (sustained cardiometabolic and annual calcaneal %YAM / TRACP-5b skeletal preservation).